AMPH Amphastar Pharmaceuticals Inc

Price (delayed)

$17.27

Market cap

$819.17M

P/E Ratio

575.67

Dividend/share

N/A

EPS

$0.03

Enterprise value

$791.93M

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

Amphastar Pharmaceuticals's revenue has increased by 9% YoY and by 3.7% QoQ
The company's gross profit rose by 9% YoY and by 2.5% QoQ
The stock's P/E is 123% more than its last 4 quarters average of 258.3
The EPS has plunged by 97% YoY and by 80% from the previous quarter

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
47.43M
Market cap
$819.17M
Enterprise value
$791.93M
Valuations
Price to earnings (P/E)
575.67
Price to book (P/B)
2.04
Price to sales (P/S)
2.32
EV/EBIT
148.94
EV/EBITDA
30.69
EV/Sales
2.26
Earnings
Revenue
$349.85M
EBIT
$5.32M
EBITDA
$25.81M
Free cash flow
$23.41M
Per share
EPS
$0.03
Free cash flow per share
$0.5
Book value per share
$8.47
Revenue per share
$7.44
TBVPS
$12.56
Balance sheet
Total assets
$631.24M
Total liabilities
$182.51M
Debt
$67.27M
Equity
$402.31M
Working capital
$167.48M
Liquidity
Debt to equity
0.17
Current ratio
2.49
Quick ratio
1.57
Net debt/EBITDA
-1.06
Margins
EBITDA margin
7.4%
Gross margin
41%
Net margin
0.4%
Operating margin
3.1%
Efficiency
Return on assets
0.2%
Return on equity
0.4%
Return on invested capital
1.2%
Return on capital employed
1%
Return on sales
1.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-0.17%
1 week
0.94%
1 month
-4.43%
1 year
5.69%
YTD
-14.12%
QTD
-5.73%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$349.85M
Gross profit
$143.34M
Operating income
$10.95M
Net income
$1.4M
Gross margin
41%
Net margin
0.4%
The net income has plunged by 97% YoY and by 79% from the previous quarter
AMPH's net margin has dropped by 97% year-on-year and by 80% since the previous quarter
The operating income has increased by 40% since the previous quarter
AMPH's operating margin is up by 35% since the previous quarter

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
P/E
575.67
P/B
2.04
P/S
2.32
EV/EBIT
148.94
EV/EBITDA
30.69
EV/Sales
2.26
The stock's P/E is 123% more than its last 4 quarters average of 258.3
The EPS has plunged by 97% YoY and by 80% from the previous quarter
The price to book (P/B) is 18% lower than the 5-year quarterly average of 2.5 and 11% lower than the last 4 quarters average of 2.3
Amphastar Pharmaceuticals's equity has increased by 5% YoY
AMPH's price to sales (P/S) is 22% less than its 5-year quarterly average of 3.0 and 10% less than its last 4 quarters average of 2.6
Amphastar Pharmaceuticals's revenue has increased by 9% YoY and by 3.7% QoQ

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The company's return on assets has shrunk by 98% YoY and by 82% QoQ
The ROE has plunged by 97% YoY and by 76% from the previous quarter
The ROS has plunged by 92% YoY and by 57% from the previous quarter
The ROIC has dropped by 92% year-on-year and by 54% since the previous quarter

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
AMPH's total liabilities is up by 14% year-on-year and by 12% since the previous quarter
Amphastar Pharmaceuticals's current ratio has decreased by 13% from the previous quarter and by 12% YoY
AMPH's debt is 83% smaller than its equity
Amphastar Pharmaceuticals's debt to equity has increased by 6% from the previous quarter
Amphastar Pharmaceuticals's equity has increased by 5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.